Geode Capital Management, LLC E Ffector Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$0.37 - $0.69 $53,359 - $99,509
144,216 Added 54.68%
407,974 $191,000
Q3 2023

Nov 13, 2023
BUY
$0.49 - $0.88 $77,800 - $139,722
158,776 Added 151.24%
263,758 $158,000
Q1 2023

May 15, 2023
SELL
$0.35 - $0.67 $477 - $913
-1,364 Reduced 1.28%
104,982 $36,000
Q1 2022

May 13, 2022
BUY
$3.85 - $8.2 $40,598 - $86,468
10,545 Added 11.01%
106,346 $426,000
Q4 2021

Feb 11, 2022
BUY
$5.71 - $13.15 $409,955 - $944,117
71,796 Added 299.09%
95,801 $793,000
Q3 2021

Nov 12, 2021
BUY
$8.56 - $27.17 $205,482 - $652,215
24,005 New
24,005 $337,000

Others Institutions Holding EFTR

# of Institutions
5
Shares Held
6.46M
Call Options Held
0
Put Options Held
0
View Full List

About eFFECTOR Therapeutics, Inc.

EFTR Quotes by TradingView
  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email